SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001714899-20-000041
Filing Date
2020-04-22
Accepted
2020-04-22 16:35:53
Documents
8
Period of Report
2020-06-03
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A fy19def14aproxy.htm DEF 14A 1100653
2 ceopaymix1.jpg GRAPHIC 61653
3 image11.jpg GRAPHIC 26538
4 image21.jpg GRAPHIC 26538
5 indexedtsr1.jpg GRAPHIC 48701
6 neopaymix1.jpg GRAPHIC 64257
7 proxyimage11.jpg GRAPHIC 1078802
8 proxyimage21.jpg GRAPHIC 1757501
  Complete submission text file 0001714899-20-000041.txt   5316961
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 20808275
SIC: 2836 Biological Products, (No Diagnostic Substances)